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Abstract
The present study aimed to determine the associations between insomnia and cardiovascular diseases (CVDs) using Men-
delian randomisation (MR) analysis. As instrumental variables, we used 208 independent single-nucleotide polymorphisms 
associated with insomnia at the genome-wide significance threshold in a meta-analysis of genome-wide association studies 
in the UK Biobank and 23andMe including a total of 397 959 self-reported insomnia cases and 933 057 non-cases. Sum-
mary-level data for nine CVDs were obtained from the UK Biobank including 367 586 individuals of European ancestry. 
After correction for multiple testing, genetic liability to insomnia was associated with higher odds of six CVDs, including 
peripheral arterial disease (odd ratio (OR) 1.22; 95% confidence interval (CI), 1.21, 1.33), heart failure (OR 1.21; 95% CI, 
1.13, 1.30), coronary artery disease (OR 1.19; 95% CI, 1.14, 1.25), ischaemic stroke (OR 1.15; 95% CI, 1.06, 1.25), venous 
thromboembolism (OR 1.13; 95% CI, 1.07, 1.19) and atrial fibrillation (OR 1.10; 95% CI, 1.05, 1.15). There were suggestive 
associations for aortic valve stenosis (OR, 1.17; 95% CI, 1.04, 1.32) and haemorrhagic stroke (OR 1.14; 95% CI, 1.00, 1.29) 
but no association for abdominal aortic aneurysm (OR, 1.14, 95% CI, 0.98, 1.33). The patterns of associations remained 
with mild attenuation in multivariable MR analyses adjusting for genetically correlated phenotypes and potential mediators, 
including sleep duration, depression, body mass index, type 2 diabetes and smoking. The present MR study suggests potential 
causal associations of genetic liability to insomnia with increased risk of a broad range of CVDs.
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Introduction
Insomnia is the commonest sleep disorder and the second 
most prevalent mental disorder, and is featured by difficulty 
initiating or maintaining sleep, early-morning awakenings, 
or having a feeling of nonrestorative sleep [1, 2]. Cardio-
detrimental effects of insomnia have been recognized by pro-
spective observational studies [3–6], especially on coronary 
heart disease [6–8], heart failure [6, 8, 9], ischemic stroke 
[7, 8], and atrial fibrillation [8, 10]. However, available data 
on the role of insomnia in certain cardiovascular diseases 
(CVDs), such as venous thromboembolism, peripheral 
arterial disease, aortic valve stenosis and abdominal aortic 
aneurysm, is limited. In addition, given that the majority 
of epidemiological evidence on insomnia and CVDs was 
embedded in an observational design, which is less likely to 
fully account for confounding and reverse causation bias, the 
causality of the associations between insomnia and various 
CVDs remains unestablished. Randomized controlled trials 
on this topic are impractical due to ethical consideration and 
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exhausting source demand. Thus, whether insomnia can be 
treated as a potentially modifiable cardiovascular risk fac-
tor, which has been proposed by previous literature [11, 12], 
needs further assessment.
Employing genetic variants as instrumental variables 
for an exposure (e.g., insomnia), Mendelian randomisa-
tion (MR) is an analytical approach empowering the causal 
inference on an exposure-outcome association by reducing 
residual confounding and reverse causality [13, 14]. The 
association obtained from MR analysis is less likely to be 
biased by confounding since genetic variants are randomly 
allocated at conception and therefore, the trait is generally 
not correlated to other traits. This natural randomisation 
process resembles the random assignment of participants 
to experimental and control groups in a randomized con-
trolled trial, which means individuals with genetic variants 
leading to a higher liability to insomnia will on average be 
exposed to a higher risk of having insomnia compared with 
their counterparts with the genetic variants related to lower 
liability to insomnia. The MR analysis also diminish reverse 
causality as genetic variants are fixed and cannot be modified 
by onset or progression of CVDs. Hence, if a genetic variant 
that alters the liability to insomnia is also related to CVDs, 
this provides strong evidence that the insomnia is a cause of 
CVDs. As far as we know, the causal associations between 
insomnia and a broad range of CVDs have not been estab-
lished using MR. We, therefore, applied an MR framework 
to determine the causal associations of insomnia with nine 
CVDs. Given that insomnia was genetically correlated with 
other phenotypes and potential mediators, including sleep 
duration, depression, body mass index, type 2 diabetes, and 
smoking [1], we aimed to disentangle the direct effect of 
insomnia on CVDs whilst accounting for these factors by 
using the multivariable MR method.
Methods and materials
Study design
Figure  1 shows the overview of study design. Genetic 
instrument selection was based on a large-scale genome-
wide association study (GWAS) for insomnia [1]. Data 
for the associations of the insomnia-associated SNPs with 
9 CVDs were available from UK Biobank [15]. Data for 
sleep duration [1], depression [16], body mass index [17], 
type 2 diabetes [18], and smoking initiation [19] were avail-
able from corresponding GWASs. Detailed information on 
data sources used is available in Supplementary Table 1. 
Several MR methods were used to assess the associations 
between genetic liability to insomnia and nine CVDs. The 
UK Biobank study was approved by the North West Multi-
center Research Ethics Committee. Original studies included 
in used GWAS had been approved by a relevant review 
board. The present analyses were approved by the Swedish 
Ethical Review Authority.
Genetic instruments selection
Single-nucleotide polymorphisms (SNPs) associated with 
insomnia at the genome-wide significance level (p < 5 ×  10–8) 
were extracted from a meta-analysis of two GWASs includ-
ing a total of 1,331,010 individuals (386 533 individuals 
from UK Biobank and 944,477 individuals from 23andMe) 
of European ancestry [1]. Insomnia was defined by self-
reported information, which was collected via a question-
naire in a touchscreen device in UK Biobank and an online 
questionnaire survey in 23andMe. The questionnaire in 
the UK Biobank had high sensitivity (98%) and specificity 
(96%) compared to Insomnia Severity Index or Pittsburgh 
Sleep Quality Index. The phenotypes in the UK Biobank and 
23andMe had acceptable sensitivity and specificity (> 80%) 
compared with the phenotype defined by structured inter-
view. There were 109,402 cases and 277,131 non-cases in 
the UK Biobank and 288,557 cases and 655,920 non-cases 
in 23andMe. Identification of lead SNPs and genomic risk 
loci was based only on SNPs that were available in both 
the UK Biobank and 23andMe sample. The GWAS identi-
fied 248 lead SNPs, located in 202 loci (> 250 kb apart), 
explaining ~ 2.6% of the variance in insomnia. The linkage 
disequilibrium across 248 SNPs were estimated using clump 
function in the TwoSampleMR package [20] based on the 
1000 genomes LD reference panel of only Europeans [21]. 
Among these, 208 independent SNPs (defined as  r2 < 0.01 
and clump window > 10,000 kb) were proposed as instru-
mental variables for insomnia. The association tests were 
adjusted for age, sex, genotype array, and 10 genetic prin-
cipal components in the UK Biobank, and age, sex and the 
top five principal components in 23andMe.
UK biobank
Summary-level statistic for the insomnia-associated SNPs 
with the 9 CVDs came from the UK Biobank, that is, a 
cohort study of about 500,000 adults aged 37–73 years and 
enrolled between 2006 and 2010 [15]. Non-Europeans were 
excluded to minimize confounding by ancestry. In addition, 
we excluded individuals with relatedness of third degree 
or higher, low genotype call rate (three or more standard 
deviations from the mean) and excess heterozygosity. We 
had a final study sample of 367 586 individuals of European 
descent who were followed up until the 31st March 2017 
(hospital episode statistics) or the 22nd March 2019 (death 
certificates). The median follow-up was 8.0 years. CVDs 
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were defined based on electronic health records, hospital 
procedure codes, and self-reported information validated by 
interview with a nurse (Supplementary Table 3). The asso-
ciation tests were conducted using logistic regression with 
adjustment for age, sex, ten genetic principal components 
to obtain the beta coefficients and standard errors for the 
SNP-CVD associations.
Statistical analysis
The inverse-variance weighted model with random-effects 
was employed as the main statistical analysis. Ratio estimates 
are calculated for each SNP using the formula: Ratio = beta 
coefficient for the SNP-CVD association/beta coefficient 
for the SNP-insomnia association. These estimates are then 
combined in a random-effects inverse-variance weighted 
meta-analysis. Estimates from this method have the high-
est precision and rely on the assumption that all SNPs are 
valid instrumental variables [22]. We used the I2 statistic to 
measure the heterogeneity among estimates across individ-
ual SNPs [23]. The weighted median and MR-Egger regres-
sion approaches were used as sensitivity analyses to test the 
robustness of the results and correct for pleiotropy. The 
weighted median method can generate consistent estimates 
if at least 50% of the weight in the analysis comes from 
valid instrumental variables [24]. The MR-Egger approach 
can detect and correct for directional pleiotropy albeit with 
compromised power [25].
Multivariable MR analyses were conducted to exam-
ine the direct effect of insomnia on CVD outcomes whilst 
accounting for potential mediation or confounding effects by 
sleep duration, depression, body mass index, type 2 diabetes 
and smoking, which are genetically correlated with insomnia 
Fig. 1  Overview of study design BMI indicates body mass index; 
CVD, cardiovascular disease; GWAS genome-wide associations 
study; IVW inverse-variance weighted; SNP single-nucleotide poly-
morphisms. T2DM, type 2 diabetes mellitus. Data extracted were 
beta coefficients with corresponding standard errors of the SNP–
insomnia, SNP-CVDs, SNP-depression, SNP-sleep duration, SNP-
BMI, SNP-smoking and SNP-T2DM associations.
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[1]. Given the strong genetic correlation between insomnia 
and depression in particular (rg = 0.5), we conducted an MR 
analysis to assess the impact of genetic predisposition to 
depression on nine CVDs in addition to the multivariable 
MR analysis adjusting for genetic liability to depression. 
We adopted the multivariable MR model solely for testing 
mediation by these factors, rather than allowing for inde-
pendent effects of these factors and their mediations effects 
simultaneously.
We used the Bonferroni method to correct for multiple 
testing. The association with two-sided p-values < 0.006 
(where α = 0.05/9 CVD outcomes) were deemed statistically 
significant and also considered strong evidence of a causal 
association. Associations with p-values between 0.05 and 
0.006 were regarded as suggestive evidence of association. 
All analyses were performed using the mrrobust package 
[26] in Stata/SE 15.0 (Stata Statistical Software: Release 
15. College Station, TX: StataCorp LLC.) and the TwoSam-
pleMR [20] and MendelianRandomization [27] packages in 
R Software 3.6.0 (R Core Team. R Foundation for Statisti-




The prevalence of insomnia was 29.9% in the combined 
population of UK Biobank and 23andMe. Two-thirds of 
the sample were older than 45 and one-third of participants 
were older than 60 years of age in 23andMe. The mean age 
of participants was approximately 57 years and ~ 46% were 
men in the UK Biobank study. The F statistic for the score of 
208 instrumental variables was ~ 143.2 in the UK Biobank.
Association of genetic liability to insomnia 
with CVDs
Genetic liability to insomnia was significantly positively 
associated with 6 out of 9 outcomes in the main analysis 
(Figs. 2, 3). For one-unit increase in log odds of insom-
nia (equalling to one-unit increase in the prevalence of 
insomnia), the odds ratios were 1.22 (95% CI, 1.21, 1.33) 
for peripheral arterial disease, 1.21 (95% CI, 1.13, 1.30) for 
heart failure, 1.19 (95% CI, 1.14, 1.25) for coronary artery 
disease, 1.15 (95% CI, 1.06, 1.25) for ischaemic stroke, 1.13 
(95% CI, 1.07, 1.19) for venous thromboembolism and 1.10 
(95% CI, 1.05, 1.15) for atrial fibrillation. There were sug-
gestive associations of genetic liability to insomnia with 
aortic valve stenosis (OR, 1.17; 95% CI, 1.04, 1.32) and 
Fig. 2  Associations of genetic liability to insomnia with 9 cardiovas-
cular diseases in UK Biobank. CI indicates confidence interval; OR 
odds ratio. Estimates are from the random-effects inverse variance-
weighted method. The I2 statistic quantifies the amount of heteroge-
neity among estimates based on individual SNPs. Significant at the 
Bonferroni-corrected threshold of p < 0.006
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haemorrhagic stroke (OR 1.14; 95% CI, 1.00, 1.29), but 
limited evidence supporting a causal association of genetic 
liability to insomnia with abdominal aortic aneurysm (OR, 
1.14, 95% CI, 0.98, 1.33). Results remained consistent in the 
sensitivity analysis using the weighted median method, but 
possible pleiotropy was detected in the analyses of haemor-
rhagic stroke and venous thromboembolism (Supplementary 
Table 4). After correcting for pleiotropy in the MR-Egger 
analysis, genetic liability to insomnia showed a suggestive 
positive association with haemorrhagic stroke (OR 2.06; 
95% CI, 1.25, 3.39).
Genetic liability to depression was significantly associ-
ated with coronary artery disease and heart failure (Supple-
mentary Fig. 1). In the multivariable MR analysis adjust-
ing for depression, the magnitude of associations of genetic 
liability to insomnia with CVDs attenuated and was only 
statistically significant at the Bonferroni corrected p value 
for aortic valve stenosis, coronary artery disease and heart 
failure (Supplementary Fig. 2). Likewise, after adjustment 
for sleep duration, most associations between genetic liabil-
ity to insomnia and CVDs attenuated slightly and only the 
associations with peripheral artery disease, heart failure and 
coronary artery disease remained significant at the Bonfer-
roni-corrected significance level (Supplementary Fig. 3).
Genetic liability to insomnia was positively associated 
with body mass index, smoking and type 2 diabetes (Supple-
mentary Fig. 4). In the multivariable MR analysis adjusting 
for these genetically correlated phenotypes, the effect sizes 
of associations attenuated mildly, whereas the overall pat-
terns for the associations of insomnia with CVD outcomes 
remained (Supplementary Fig. 5). The association with 
aortic valve stenosis did not persist in the multivariable MR 
analysis adjusting for body mass index.
Discussion
Principal findings
The present study based on genetic data for 367 586 women 
and men found that genetic liability to insomnia was associ-
ated with higher risk of a broad range of CVDs. The strong-
est associations were observed for peripheral arterial dis-
ease, heart failure, coronary artery disease, ischaemic stroke, 
venous thromboembolism and atrial fibrillation. There were 
suggestive associations for aortic valve stenosis and haemor-
rhagic stroke but no association for abdominal aortic aneu-
rysm. The pattern of associations remained after adjustment 
for genetically predicted sleep duration and genetic liability 
to depression. Genetic predisposition to insomnia appeared 
to influence body mass index, type 2 diabetes and smoking 
in an unfavourable manner and these factors might partly 
mediate the link from insomnia to these CVDs.
Previous studies
The majority of previous observational studies identified 
that insomnia was associated with increased risk of over-
all CVDs in both Western and Eastern populations [3, 5, 
6], which was supported by the present MR study. When 
looking at specific CVD outcomes, our results were also in 
Fig. 3  Genetic liability to 
insomnia in relation to cardio-
vascular diseases
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agreement with the findings suggesting that insomnia is a 
risk factor for coronary heart disease [3, 6–8], heart failure 
[6, 8, 9], ischemic stroke [3, 7, 8] and atrial fibrillation [8, 
10]. A previous MR study using data from genetic consortia 
found a major influence of insomnia on four common CVDs, 
including coronary artery disease, heart failure, atrial fibril-
lation and ischemic stroke [8]. Our findings were direction-
ally consistent with the previous MR study, but the estimates 
were of somewhat stronger magnitude. The reason behind 
the discrepancy in effect size might be a more consistent 
case definitions in UK Biobank, dilution effects introduced 
by population mixture in large consortia or differences in 
insomnia status and prevalence of other risk factors in dif-
ferent populations.
Epidemiological evidence on the associations of insom-
nia with peripheral arterial disease, venous thromboembo-
lism and abdominal aortic aneurysm is scarce. Mechanistic 
findings may lend supports to these novel associations. In 
detail, studies revealed a higher level of von Willebrand 
factor [28] and inflammation [29] that facilitate the pro-
cess of coagulation and atherosclerosis among individuals 
with shorter sleep duration. Although we noticed a general 
adverse impact of insomnia on CVDs, the present study pro-
vided limited evidence in support of causal associations of 
insomnia with aortic valve stenosis, haemorrhagic stroke 
and abdominal aortic aneurysm. The possible reason may 
be small number of cases of these outcomes, and therefore, 
inadequate power in these analyses.
Insomnia had a high genetic correlation with depres-
sion [1], which may pose an overall risk on CVDs based 
on a mechanistic analysis [30] and may be a confounder in 
observed association between insomnia and CVDs. None-
theless, except for effects on coronary artery disease and 
heart failure, the present and a previous MR study [31] did 
not reveal any causal associations between genetic liability 
to depression and CVDs. After adjusting for genetic predis-
position to depression, the associations of insomnia with 
coronary artery disease and heart failure remained and the 
magnitude of the association for heart failure became even 
stronger, which suggests genetically correlated depression 
with insomnia is less likely to be a source biasing the asso-
ciations between insomnia and CVDs. Similarly, the pattern 
of associations of genetic liability to insomnia with CVDs 
remained after adjustment for genetically predicted sleep 
duration, which might indicate our findings was less likely 
to be covered by the genetic correlation between insomnia 
and sleep duration.
Genetic liability to insomnia appeared to exert a causal 
effect on body mass index, type 2 diabetes and smoking in 
an unfavourable manner. These factors might partly mediate 
the associations between insomnia and CVDs. We found 
some support for this as the associations between genetic 
liability to insomnia and CVDs were slightly attenuated in 
multivariable MR analyses with adjustment for these factors.
Potential mechanisms
Detailed pathophysiological bases behind the association 
between insomnia and CVDs are not fully understood. 
There are several hypotheses supporting such link. At the 
macro level, insomnia was found to be causally associated 
with several risk factors in a bad manner, such as body mass 
index, smoking and type 2 diabetes in the present and pre-
vious study. Increased body mass index [32], smoking [33] 
and type 2 diabetes [34] were identified to possibly trigger 
CVDs. At the micro level, insomnia is a disorder of hypera-
rousal with chronic activation of stress responses conse-
quently accompanied by increased metabolic rate, increased 
heart rate and decreased heart rate variability, and increased 
cortisol secretion. Such insomnia-derived abnormalities in 
the autonomic nervous system and hypothalamic pituitary 
axis may partly explain the increased risk of CVDs among 
insomnia patients [35]. The elevated blood pressures among 
insomnia patients may also partly solidify the causal associa-
tion linking insomnia to cardiovascular disease [36]. In addi-
tion, insomnia itself can induce alternations in inflammation, 
oxidative stress, and dyslipidaemia, which further lead to an 
increase in arterial blood pressure, endothelial dysfunction, 
diabetes mellitus, and accelerated atherosclerosis [12].
Validation of assumptions of MR
There are three assumptions of MR that need to be satisfied 
to determine causality in an MR analysis. First, the genetic 
variants used as instrumental variables should be robustly 
associated with the risk factor, in this case, insomnia. In the 
present study, genetic instruments associated with insomnia 
were selected from a large-scale GWAS including 1 331 
010 individuals at p < 5 ×  10–8. Second, the selected genetic 
variants should not be associated with potential confound-
ers. Even though genetic instruments for insomnia were 
associated with sleep duration and depression that might 
be confounders, the multivariable MR analysis adjusting 
for these factors revealed that the pattern of associations of 
insomnia with CVD persisted. Thirdly, the genetic variants 
should affect the risk of the outcome, in this case CVD, only 
through the risk factor, not via alternative pathways. This 
assumption was also satisfied by conducting multivariable 
MR analyses adjusting for depression, smoking and type 2 
diabetes. These analyses suggested that depression, smok-
ing and type 2 diabetes may be mediators of the relationship 
between insomnia and CVD.
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Strengths and limitations
Our study has several strengths. The major one is the MR 
design, which reduced the possibility that the observed asso-
ciations were biased by confounding and other biases. The 
associations of insomnia with type 2 diabetes and coronary 
artery disease were revealed in the GWAS on insomnia [1] 
and successfully replicated in the present study indicating 
the genetic instrument for insomnia robustly associated with 
insomnia, thereby providing a strong genetic instrument. In 
addition, the statistical power was high in analyses of preva-
lent cardiovascular outcomes in UK Biobank. Finally, we 
only included participants of European descent in the expo-
sure and outcome datasets, so population stratification bias 
was minimized. However, this population confinement might 
on the other hand limit the generalizability of our findings 
to other populations.
The present study also has several limitations. First, we 
could not completely expel the possibility that the insomnia-
related SNPs affect CVDs through other causal pathways 
than through insomnia. However, major genetically cor-
related traits, such as sleep duration and depression were 
adjusted for in multivariable MR analyses and the associa-
tions remained stable with slight attenuation after the adjust-
ment. Second, we might have missed weak associations 
given the small number of cases for certain CVDs, in par-
ticular haemorrhagic stroke and abdominal aortic aneurysm. 
Another limitation is that there was a partial (approximately 
27.6%) overlap between the exposure (insomnia) and out-
come (CVD) datasets, which could lead to model overfitting 
[37]. This limitation might bias the causal estimates towards 
the direction of the observational association between 
insomnia and CVD risk [37]. However, an F-statistic > 10 
for the genetic risk score revealed that the used instrumental 
variables are strongly associated with the exposure [37]. In 
addition, our results were in agreement with findings based 
on large consortia data with less or no overlap [8]. Thus, any 
potential bias due to sample overlap is expected to be small.
Conclusions
The present MR study reveals evidence supporting causal 
associations of genetic liability to insomnia with a broad 
range of CVDs, in particular peripheral arterial disease, 
heart failure, coronary artery disease, ischaemic stroke, 
venous thromboembolism and atrial fibrillation. Strategies 
to reduce insomnia may be one of the cornerstones in the 
prevention of CVDs.
Supplementary Information The online version contains supplemen-
tary material available at https ://doi.org/10.1007/s1065 4-021-00737 -5.
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